Clinical Trial Update: Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis® [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating efficacy, safety, pharmacokinetics, and immunogenicity of GNR-067 in Age Related Macular Degeneration (ARMD). Status not specifi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• GNR-067
• Lucentis (ranibizumab)

Snippet

Sponsor: AO GENERIUM | Conditions: Age Related Macular Degeneration (ARMD) | Phase 3 | Status: UNKNOWN